Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod Alone and in Combination With IRd for Relapsed or Refractory Myeloma
NCT04405167Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasquinimod in multiple myeloma (MM) (4 arms), sponsored by University of Pennsylvania. Primary endpoint: Optimal Dose at 3 years. Started Jul 2020; status: terminated.
02
Drugs
tasquinimod
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04405167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405167.